[
  {
    "ts": "2026-02-19T02:33:53+00:00",
    "headline": "Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited",
    "summary": "AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks. TheFly reported on February 4 that Evercore ISI lowered its price target on ABBV to $228 from $232 and maintained an Outperform rating. The firm noted that although Tremfya […]",
    "url": "https://finance.yahoo.com/news/evercore-notes-abbvie-inc-abbv-023353428.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c4562fe0-3008-33c3-874e-1ef5db2a6d26",
      "content": {
        "id": "c4562fe0-3008-33c3-874e-1ef5db2a6d26",
        "contentType": "STORY",
        "title": "Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks. TheFly reported on February 4 that Evercore ISI lowered its price target on ABBV to $228 from $232 and maintained an Outperform rating. The firm noted that although Tremfya […]",
        "pubDate": "2026-02-19T02:33:53Z",
        "displayTime": "2026-02-19T02:33:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Evercore Notes AbbVie Inc.'s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evercore-notes-abbvie-inc-abbv-023353428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evercore-notes-abbvie-inc-abbv-023353428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]